Clik here to view.
Evaluate Ltd’s Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In
LONDON & BOSTON & SAN FRANCISCO & TOKYO Today life science commercial intelligence leader, Evaluate, released case studies highlighting the value of granular patient segmentation and...
View ArticleClik here to view.
Masimo宣布rainbow®多波长脉搏灌注变异指数无创RPVi™获得CE标记
瑞士纳沙泰尔 (美国商业资讯) — Masimo (NASDAQ: MASI)今天宣布，RPVi™获得CE标记，RPVi是一个或多个呼吸周期中灌注指数(Pi)所发生的动态变化的无创连续测量指标。RPVi可显示某些生理因素（例如血管张力、循环血容量、胸内压位移）的变化。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
マシモ、rainbow®対応の多派長脈波変動指標となる非侵襲的RPVi™のCEマーク取得を発表
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、RPVi™がCEマークを取得したと発表しました。RPVi™は、1回以上の呼吸周期における灌流指標（Pi）の動的変化を非侵襲的かつ連続的に測定した値です。RPViは血管緊張度、循環血液量、胸腔内圧変動などの生理学的因子を反映した変化を示すようにデザインされています。 このSmart News...
View ArticleClik here to view.
SpinalCyteが新たな日本国特許を取得
ヒューストン テキサスに拠点を置き、ヒト皮膚線維芽細胞を使用した椎間板髄核の再生に傾注する組織工学技術企業のSpinalCyte, LLCは本日、日本国特許第6151006号「生体内バイオリアクターを使用した軟骨修復のための方法と組成物」の登録を発表しました。...
View ArticleClik here to view.
ニューランド・ラボラトリーズがプロセスエンジニアリング専用ラボを公開
印ハイデラバード （ビジネスワイヤ） — 約80カ国の顧客に医薬品有効成分（API）、中間複合体、カスタム化製造ソリューションの各サービスを提供する製薬会社のニューランド・ラボラトリーズ・リミテッド（NLL）（NSE: NEULANDLAB、BSE-Scrip...
View ArticleClik here to view.
Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced the launch of RENFLEXIS™ (infliximab-abda), a biosimilar referencing Remicade® (infliximab), in the United States (US). RENFLEXIS™ was...
View ArticleClik here to view.
Optibrium and Bugworks Sign Agreement for StarDrop License
CAMBRIDGE, United Kingdom & BENGALURU, India Optibrium™, a developer of software for small molecule discovery, and Bugworks Research Inc. (Bugworks), a company focused on discovering...
View ArticleClik here to view.
Co-Diagnostics, Inc. Announces Joint Venture in India
SALT LAKE CITY Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic...
View ArticleClik here to view.
Takeda and BioSurfaces Announce Joint Research Program to Explore Promising...
CAMBRIDGE & ASHLAND, Mass. Takeda Pharmaceutical Company Limited (TSE: 4502) and BioSurfaces Inc. announced today that they have entered into an agreement to initiate a research program designed...
View ArticleClik here to view.
Foxconn Selects Wisconsin with Commitment to High-Tech Manufacturing
MADISON, Wis. Foxconn Technology Group (Foxconn), has announced this afternoon that the company will be building a high-tech display manufacturing plant and technology campus in Southeastern...
View ArticleClik here to view.
CHMP对杨森公司治疗HIV的首个含Darunavir的单一片剂方案SYMTUZA™签发肯定意见
比利时贝尔塞 (美国商业资讯) — Janssen-Cilag International NV（杨森）今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)已签发一项肯定意见，推荐核准SYMTUZA™（darunavir/cobicistat/恩曲他滨/替诺福韦艾拉酚胺[D/C/F/TAF]）上市，该药是含darunavir的单一片剂方案(STR)，每天一次给药。...
View ArticleClik here to view.
ヤンセン、ダルナビルを基本とした初のHIV治療用シングルタブレットレジメンSYMTUZA™に対するCHMPの肯定的意見を取得
ベルギー・ベーアセ （ビジネスワイヤ） —...
View ArticleClik here to view.
Cogstate Receives Positive FDA Notification Regarding Medical Device...
BOSTON The cognitive science company, Cogstate today announced that its healthcare division has received notification from the U.S. Food and Drug Administration (FDA) that the Company’s 510(k)...
View ArticleClik here to view.
New CDISC Standard Empowers Smarter Research for Diabetic Kidney Disease
AUSTIN, Texas The Clinical Data Interchange Standards Consortium (CDISC) is pleased to announce the availability of a new Therapeutic Area Standard for Diabetic Kidney Disease in the form of a User...
View ArticleClik here to view.
Astellas Reports First Quarter FY2017 Financial Results
TOKYO Astellas Pharma Inc. (TOKYO:4503)(President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first quarter of fiscal year 2017 (“FY2017”), ending March...
View ArticleClik here to view.
Takeda Reports 1st Quarter FY2017 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth of 6.6% led by Takeda’s Growth Drivers Underlying Revenue grew +6.6% with growth across all regions (U.S....
View ArticleClik here to view.
武田薬品: 2017年度第1四半期の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 実質的な売上収益の成長は6.6％の増収、成長ドライバーが牽引...
View ArticleClik here to view.
武田公布2017财年第一季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TOKYO: 4502)： 武田增长引擎带动基础营收增长 6.6% 基础营收增长+6.6%，各地区业务均有所增长（美国+13.5%、日本 +1.6%、欧洲与加拿大 +4.6%、 新兴市场...
View ArticleClik here to view.
Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License...
INCHEON, Republic of Korea & JERUSALEM Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted...
View ArticleClik here to view.
Study Compares Performance of Masimo Acoustic Respiration Rate (RRa®) and...
TOKYO Masimo (NASDAQ: MASI) announced today that researchers at the Tokyo Women’s Medical University, Department of Anesthesiology, in Japan have published a study investigating the measurement of...
View Article